Business context and reporting period
The supplied filing is Amarillo Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2012—not a standalone fourth-quarter report. This differs from the request metadata, which names Ainos, Inc. The company was developing low-dose oral interferon biologics, principally for influenza, and had not begun significant commercialization. It also had a dry-mouth dietary supplement, Maxisal.
Financial results and position
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue | $530 | $58,395 |
| Gross profit | $318 | $54,041 |
| R&D expense | $199,599 | $281,107 |
| SG&A expense | $355,327 | $918,814 |
| Operating loss | $554,608 | $1,145,880 |
| Net loss | $650,847 | $1,313,773 |
| Net loss applicable to common shareholders | $681,698 | $1,330,729 |
| Net cash used in operating activities | $489,442 | $309,705 |
At year-end, cash was $7,261, current assets were $20,935, and current liabilities were $4,242,330, leaving a working-capital deficit of $4,221,395. Total assets were $115,035 and stockholders’ deficit was $4,127,295. Current liabilities included two HBL notes totaling $2 million and $931,294 accrued interest, $200,000 owed to a director, and $547,958 in related-party working-capital loans. The HBL notes were in default; HBL had not demanded payment as of the filing date. The company reported an approximately $50,000 monthly burn rate. No standalone gross-margin percentage is stated; gross profit was $318 on $530 of revenue.
Changes versus 2011
Revenue fell by $57,865, or about 99%, as sublicense fees declined from $50,000 to zero and product sales fell from $8,395 to $530. Operating expenses decreased by $644,995, led by lower SG&A, so the net loss narrowed by $662,926. Despite the lower reported loss, operating cash use increased by $179,737. The company issued 1,995,108 common shares in 2012, primarily for debt conversion; it issued no common shares for cash in 2012. Related-party notes increased, while total current liabilities rose slightly to $4.24 million.
Outlook, risks and unusual items
- Going concern and funding: The auditor’s report and management disclosures raise substantial doubt about the company’s ability to continue as a going concern. The company expected further losses, needed additional financing to execute its 2013 plan, and warned that failure to raise funds could force it to curtail operations or cease business.
- Interferon supply and partnerships: Hayashibara Company (HBC) stopped interferon production and terminated the supply/development agreement effective December 22, 2012. The company had no current interferon supply for trials or sublicensees and was exploring alternative suppliers. Agreements with Bumimedic, Intas and CytoPharm were likely to be terminated or had been given termination notice because supply could not be maintained.
- Clinical development: No clinical studies were ongoing at year-end. A chronic-cough study was closed in April 2012 for insufficient enrollment, with no meaningful results. A Taiwan influenza-treatment study was expected to report in the first half of 2013. A hepatitis C study missed its primary endpoint, although the filing describes exploratory findings on relapse in a subgroup and platelet-count normalization.
- Prospective funding and plans: Management was negotiating commercial development partnerships and anticipated that one or more might be executed during 2013; no assurance was given. An interim arrangement with the Yang Group supported operations through advances routed via CEO Stephen Chen. A final transaction agreement was still under negotiation. The company reported an additional $198,335 received through Chen after year-end and through March 24, 2013.
- Other notable matters: 2012 net loss included $44,096 of derivative gains, a non-cash fair-value item. Preferred stock carried a 10% annual dividend and was convertible into common shares. The company had no audit committee at year-end, although management reported effective disclosure controls and internal control over financial reporting. The auditor did not provide an internal-control attestation.
- Risks: Dependence on external financing and third-party suppliers, defaulted HBL debt, potential dilution, limited trading liquidity, regulatory and clinical uncertainty, and competition from substantially better-resourced companies.
Important facts for investors to verify
- Confirm the issuer: the filing identifies Amarillo Biosciences, Inc., not Ainos, Inc., and covers the full 2012 fiscal year.
- Check whether the company secured an alternative interferon supplier and whether the planned 2013 clinical work and commercial partnerships proceeded.
- Review the status and terms of the Yang Group arrangement, related-party advances, post-year-end funding, and any definitive transaction documents.
- Assess liquidity, the defaulted HBL notes and accrued interest, and the auditor’s going-concern warning.
- Verify the status of preferred-stock dividends and conversion rights, outstanding options and warrants, and potential shareholder dilution.